Overview

A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer

Status:
Completed

Trial end date:
2019-08-27

Target enrollment:

Participant gender:

Summary

This is a phase I/II study to find the highest dose of hydroxychloroquine that can be given safely with itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer. The study will also determine the safety, tolerability, and initially determine whether the combination is useful in the treatment of patients with advanced platinum-resistant epithelial ovarian cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University Health Network, Toronto

Treatments:

Hydroxychloroquine
Hydroxyitraconazole
Itraconazole